Homepage Top Section2

Vertex Pharmaceuticals has agreed to acquire US-based biotech company Semma Therapeutics for $950m (£784.66m) in an all-cash deal with an aim to develop curative cell-based treatments for type

The phase III trial has demonstrated that Xofluza was a well-tolerated and efficient potential treatment for flu in otherwise healthy children aged one to less than 12 years

Anifrolumab has demonstrated a statistically-significant and clinically-meaningful reduction in disease activity compared to placebo in the trial.  Both arms received standard of care in the study. Anifrolumab is

The approval has been granted for Tecentriq plus chemotherapy (Abraxane [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) to treat adult patients with unresectable locally advanced or metastatic

Based in Germany, Immatics is a clinical-stage biopharma company engaged in the discovery and development of T-cell redirecting cancer immunotherapies. The German firm is expected to develop T-Cell

The lead product candidate of Modis Therapeutics is MT1621, an investigational deoxynucleoside substrate enhancement therapy. Currently, MT1621 is in late-stage development for the treatment of Thymidine Kinase 2

The latest FDA approval is the third for Taltz with the first one coming in 2016 for the treatment of adults with moderate to severe plaque psoriasis. The

The company has reported positive headline results from the pivotal DREAMM-2 open-label and randomised study of two doses of belantamab mafodotin. Belantamab mafodotin is an immuno-conjugate, which included

Cabotegravir is an investigational integrase inhibitor (INI) developed by ViiV Healthcare, while Edurant (rilpivirine) has been developed by Janssen as a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the